Topic Archives: Fast Money Alert

Received an invitation today to join Fast Money Alert service bu Mark Skousen. Does anyone have any info or history with this newsletter? Sounds interesting, but as usual seems way too easy. Claims 34 trade opportunities per year with a 91% success rate and returns between 5% and 120% on trades lasting 14 to 25 […]

Comments

  • Avatar

    Thanks for the details of the financial arrangement. I am reading this a pretty negative. My only explanation is the sa...

  • Avatar

    $PTN -- The Phase 3 trial results were great and well-predicted by Doc's column which came out a few weeks earlier. Addi...

  • DrKSSMDPhD

    Hi michmana: the overall NDA/BLA cost depends a lot on how they budget things internally, and they are secretive about i...

  • Avatar

    $PTN I do believe that PTN is looking like a possible buyout. However, the large number of shares/warrants limits the ...

  • Avatar

    $PTN: A negative SA piece on Addyi & Valeant. Keeping with the concept that the enemy of my enemies are my friend, ...

  • Avatar

    PTN: They have an approved product equiv to a female viagra....sales could be MASSIVE . If nothing else, the owners of A...

  • Avatar

    Yes, totally agree with what you say jabberwocky. The trouble with the "frenzy" of rumors etc...is that they can lead to...

  • DrKSSMDPhD

    Agree. The stars are aligned here, and people need to not miss out. $ARTH will do the same in due course, I feel, but sh...

  • DrKSSMDPhD

    I don't give directed personal investing advice, but I feel very obliged to point out and emphasize the opportunity in f...

  • DrKSSMDPhD

    A $PTN buyout is plausible. Flibanserin (Addyi) was recently approved for FSD and bought by Valeant....

  • Avatar

    $PTN New Roth report out today Roth Capital Affirms Palatin Technologies (PTN) at 'Buy'; Q1 Solid and Partnership Pot...

  • DrKSSMDPhD

    $500M US sales, $1.5B ex-US, $2B globally. If they hustle, they can have BLA approval for marketing in 1H2018 by submitt...

  • Avatar

    $PTN - - some observations from the presentation. > Slide 7: "Market analysts estimate global market > $2 billi...

  • Avatar

    Doc, could you clarify for me how the Phase 3 data for Bremelanotide shows that it's significantly more efficacious than...

  • Avatar

    My opinion is that due to PTN's shaky financial situation and the fact that Addyi has been an abject failure will make t...

  • Avatar

    Not to quibble with you, bizbanx. But recall that Valeant bought Sprout for $1 billion for an abysmal drug, Addyi, which...

  • Avatar

    $PTN Copied -----For what its worth--For me it confirms the importance of doing a transaction sooner than later---PTN ha...

  • Avatar

    $PTN Canaccord aanalyst report -- "Palatin shares are rising 30% after the company’s key pipeline drug bremelanotid...

  • Avatar

    Let the games and the price negotiations begin! I seriously doubt that $PTN will settle for anything short of $300 mill...

  • Avatar

    It certainly appears that $PTN has some offers on the table although we have no idea what they are. Logically, one woul...

  • Avatar

    $PTN Already has buy-out offers??? Exclusive: Female Viagra contender Palatin Technologies explores potential sa...

  • Avatar

    Definitely Doc, although I have to work and am on PST so probably cannot. IMO, the current share price is a steal (prob...

  • Avatar

    Thanks so much Doc for the helpful update and comments. $PTN shares have been falling rather significantly in recent day...

  • Avatar

    1) Gummies interested in evaluating how the FDA's Addyi approval process will read for $PTN might want to check out the...

  • Avatar

    Also from the $PTN conference call transcript, some comparison with Addyi: "s we look forward to top line data, we are w...

  • Avatar

    I also read that alcohol is compatible with bremelanotide whereas it's contraindicated in patients on flibanserin (Addyi...

  • Avatar

    Sprout Pharma was the company bought out by Valeant for $1 billion (mentioned in the article). I agree that Addyi is a ...

  • SoGiAm

    Author: JohnM Comment: http://www.stockgumshoe.com/2016/08/ten-common-biotech-investing-mistakes/comment-page-12/#comme...

  • JohnM

    $PTN no position Slingshot Insights upcoming call Bremelanotide Phase 3 Data Is Days Away In Female Sexual Dysfunction...

  • Avatar

    After the excitement that has been our last two data readouts ($AUPH, good news, bad reception; $CLCD, great), the next ...

  • DrKSSMDPhD

    You are sorely tempting me, Sharon. I suspect this one will fetch an ad com, and will be batted around, but will win app...

  • Avatar

    $PTN Been reading through the most recent conference call with Palatin, and things are looking interesting here. Both t...

  • Avatar

    The New York Times reports that Sprout's flibanserin - once dubbed the pink viagra - has proved less than arousing. Mar...

  • DrKSSMDPhD

    First some comments about Valeant. Its action in grabbing Addyi was proof, as if proof were needed, that a top was in fo...

  • Avatar

    $PTN. Was updating myself today on this stock, which has been discussed here from time to time, and am sharing in case ...

  • DrKSSMDPhD

    Hi Jonathan: I am actually studying that situation. My biggest concern is that EU partner Gedeon Richter pulled out of t...

  • Avatar

    Doc or anyone else, any thoughts about Palatin $PTN and maybe a potential buyout? No personal position currently, but ob...

  • DrKSSMDPhD

    Hi Curt: Not bremelanotide, but PTN has licenses to other brain-acting peptides that are believed to have potent appetit...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info